It is likely that social determinants of health (SDOH) may affect the differences in outcomes from multiple sclerosis (MS) that we see among Black/African American and Hispanic/Latinx populations, absent more data on their genetics and ancestry, noted Mitzi Joi Williams, MD, FAAN.
In this interview about CHIMES trial interim findings that were presented at this year’s American Academy of Neurology annual meeting, Mitzi Joi Williams, MD, FAAN, medical director and CEO, Joi Life Wellness Neurology Clinic, and an investigator on the study, discusses its next steps and the potential influence of social determinants of health/environment on multiple sclerosis (MS) in minority populations.
Transcript
Does MS manifest differently among races/ethnicities, and if so, can we infer this to mean potential environmental influences on disease course?
There are some studies suggesting that there may be a higher incidence of optic neuritis, as well as spinal cord involvement, in Black and African American and Hispanic and Latinx communities. Certainly, we know that race is a social construct, and until we can get more data in these populations about genetics and ancestry, certainly it is likely that social determinants of health, access to care, and other things may be playing a role, or environmental factors that have yet to be identified in why we're seeing some of these differences.
What are next steps for the CHIMES trial?
The findings in terms of efficacy were largely in line with what we expected to see. There was a surprise that many of the patients did come to diagnosis pretty early on after onset of symptoms. One of the reasons that has been hypothesized for why we see more severe disease in these populations has been because there's delayed diagnosis—but we really didn't see that in the CHIMES trial. So that was a surprising finding.
I think the next steps are to continue to analyze the data. We would love to have the continued retention for the full 4 years of this study, with the 3 years of extension. And to understand the genomics and ancestry, I think, will be a huge piece of this, as well as B-cell markers and biomarkers.
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Health Equity and Access Weekly Roundup: March 23, 2024
March 23rd 2024The Center on Health Equity and Access covered disparities in hypertension, diabetic eye health, and hidradenitis suppurativa, along with the proposed legislation banning diversity, equity, and inclusion efforts in Alabama schools and the consequences in sickle cell care from the CDC guideline for opioid prescriptions.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Low Screening Rates for Lung Cancer Highlight Public Health Priority
March 21st 2024Overall rates for lung cancer screening remain low, despite the US Preventive Services Task Force revising its annual screening recommendation in 2021 by lowering the age of initial screening for current or former smokers and their pack-year history.
Read More